NoGeneST™ Anti-TREM2 Aptamer, aTREM2 aptamer

Name: NoGeneST™ Anti-TREM2 Aptamer, aTREM2 aptamer
SKU: NRYF-0625-HZ88
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ88]

Aptamer designed to specifically recognize Triggering Receptor Expressed On Myeloid Cells 2, a key immunomodulatory receptor in neurodegenerative disease.

Target:: TREM2

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Species

Human

Relevant Diseases

Alzheimer's Disease

Properties

Size

5 nmol. 10 nmol. 50 nmol

Soluble In

PBS; buffer system with Serum; other

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

TREM2

Full Name

Triggering Receptor Expressed On Myeloid Cells 2

Alternative Names

TREM-2

Gene ID

54209

Uniprot ID

Q9NZC2

Target Overview

Triggering Receptor Expressed on Myeloid cells 2 (TREM2) is a transmembrane receptor primarily expressed on the surface of myeloid cells, such as microglia, the resident immune cells of the brain. It plays a critical role in regulating microglial activation, survival, and phagocytic activity-the process of clearing cellular debris and protein aggregates like amyloid-beta. Genetic variants of TREM2 are significant risk factors for developing late-onset Alzheimer's disease and other neurodegenerative disorders, making it a key target for therapeutic modulation of the brain's immune response.

Publications